Posted inGastroenterology news Oncology
Erdafitinib Yields 55% Response Rate in FGFR-Altered Advanced Cholangiocarcinoma: Insights from a Pooled Phase 2 Analysis
A pooled analysis of the RAGNAR and LUC2001 trials demonstrates that erdafitinib provides a robust objective response rate of 55% and a median overall survival of 18.1 months in pretreated patients with FGFR-altered advanced cholangiocarcinoma.